N-(1H-Benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine is a potent CXCR4 inhibitor that inhibits X4 HIV-1 replication and the gp120/CXCR4 interaction. It also has therapeutic potential for developing treatments for B-RAF wild-type and mutated melanomas.
ChEBI: AMD 070 is an aminoquinoline.
Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss[2].
125I-SDF-CXCR4: 13 nM (IC50); HIV-1 (NL4.3 strain): 1 nM (IC50, in MT-4 cells); HIV-1 (NL4.3 strain): 9 nM (IC50, in PBMCs); HIV-1 (NL4.3 strain): 3 nM (IC90, in MT-4 cells); HIV-1 (NL4.3 strain): 26 nM (IC90, in PBMCs)
